Tenax Therapeutics, Inc. (TENX) NASDAQ
Currency In USD
AD
- General
- Statistics
- Historical Data
- Profile
- Financials
AD
Currency In USD
| Previous Close | 12 |
| Open | 12.5 |
| Day High | 12.7 |
| Day Low | 11.86 |
| 52-Week High | 18.38 |
| 52-Week Low | 5.62 |
| Volume | 869,018 |
| Average Volume | 690,303 |
| Market Cap | 210.67M |
| PE | -8.69 |
| EPS | -1.41 |
| Moving Average 50 Days | 12.41 |
| Moving Average 200 Days | 11.08 |
| Change | 0.25 |
Tenax Therapeutics to Participate in the 2026 Leerink Partners Global Healthcare Conference
GlobeNewswire Inc.
Mar 03, 2026 12:00 PM GMT
CHAPEL HILL, N.C., March 03, 2026 (GLOBE NEWSWIRE) -- Tenax Therapeutics, Inc. (Nasdaq: TENX) (“Tenax” or “Tenax Therapeutics” or the “Company”), a Phase 3, development-stage pharmaceutical company using clinical insights to develop novel cardiopul
Tenax Therapeutics to Participate in the Guggenheim Emerging Outlook Biotech Summit 2026
GlobeNewswire Inc.
Feb 04, 2026 12:00 PM GMT
CHAPEL HILL, N.C., Feb. 04, 2026 (GLOBE NEWSWIRE) -- Tenax Therapeutics, Inc. (Nasdaq: TENX) (“Tenax” or “Tenax Therapeutics” or the “Company”), a Phase 3, development-stage pharmaceutical company using clinical insights to develop novel cardiopulm
Tenax Therapeutics Announces Result of Prespecifed Blinded Sample Size Assessment
GlobeNewswire Inc.
Dec 17, 2025 2:16 PM GMT
Planned Review of Standard Deviation Demonstrates No Need to Increase Size of Ongoing LEVEL Study LEVEL On Track to Complete Enrollment in First Half of 2026; Topline Data Expected in Second Half of 2026 Global Phase 3 LEVEL-2 Study Initiated; Compan